Clinical-stage biotechnology firm KBP Biosciences has secured a $76 million Series A financing round led by Advantech Capital and SDIC Venture Capital.
KBP Biosciences, a Greater Philadelphia Area and Jinan, China-based private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $76m Series A financing. The round was co-led by Advantech Capital and SDIC Venture Capital, with participation from Sangel Capital, Ping An Ventures, Bay …
